SMC2 and ovarian cancer: These findings highlight CAPE’s ability to attenuate immunosuppressive signals and shift macrophage balance from M2 to M1, thereby supporting effector T-cell function and strengthening the anti-tumour immune response within the simulated ovarian cancer microenvironment (Figure 4).